EA201990526A1 - Конъюгат миноксидила и пептида - Google Patents

Конъюгат миноксидила и пептида

Info

Publication number
EA201990526A1
EA201990526A1 EA201990526A EA201990526A EA201990526A1 EA 201990526 A1 EA201990526 A1 EA 201990526A1 EA 201990526 A EA201990526 A EA 201990526A EA 201990526 A EA201990526 A EA 201990526A EA 201990526 A1 EA201990526 A1 EA 201990526A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
hair loss
composition
stimulating
peptide
Prior art date
Application number
EA201990526A
Other languages
English (en)
Other versions
EA038745B1 (ru
Inventor
Йонг Джи Чунг
Эюн Ми Ким
Original Assignee
Кареджен Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кареджен Ко., Лтд. filed Critical Кареджен Ко., Лтд.
Publication of EA201990526A1 publication Critical patent/EA201990526A1/ru
Publication of EA038745B1 publication Critical patent/EA038745B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к композиции для предотвращения выпадения волос и, более конкретно, к соединению, имеющему структуру, в которой Миноксидил и пептид химически связаны, и к фармацевтической композиции или косметической композиции для предотвращения выпадения волос или стимуляции роста волос, включающей такое соединение. Соединение, имеющее структуру, в которой Миноксидил и пептид химически связаны, в соответствии с настоящим изобретением обладает не только отличной физиологической активностью, такой как снижение выпадения волос, стимуляция роста волос или стимулирование роста клеток, а также и превосходной стабильностью в воде, и поэтому может быть полезным в качестве композиции для предотвращения выпадения волос и стимуляции роста волос.
EA201990526A 2016-08-19 2017-08-04 Конъюгат миноксидила и пептида EA038745B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160105707A KR101948238B1 (ko) 2016-08-19 2016-08-19 미녹시딜과 펩타이드의 결합체
PCT/KR2017/008428 WO2018034453A1 (ko) 2016-08-19 2017-08-04 미녹시딜과 펩타이드의 결합체

Publications (2)

Publication Number Publication Date
EA201990526A1 true EA201990526A1 (ru) 2019-07-31
EA038745B1 EA038745B1 (ru) 2021-10-13

Family

ID=61196895

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990526A EA038745B1 (ru) 2016-08-19 2017-08-04 Конъюгат миноксидила и пептида

Country Status (16)

Country Link
US (1) US11617796B2 (ru)
EP (1) EP3501545B1 (ru)
JP (2) JP7050052B2 (ru)
KR (1) KR101948238B1 (ru)
CN (1) CN109715217B (ru)
AU (1) AU2017313589B2 (ru)
BR (1) BR112019003077A2 (ru)
CA (1) CA3034066C (ru)
CL (1) CL2019000429A1 (ru)
EA (1) EA038745B1 (ru)
ES (1) ES2933848T3 (ru)
MX (1) MX2019001921A (ru)
MY (1) MY193527A (ru)
PH (1) PH12019500345A1 (ru)
WO (1) WO2018034453A1 (ru)
ZA (1) ZA201901534B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102089754B1 (ko) * 2018-11-09 2020-03-17 주식회사 바이오셀트란 피부투과성이 개선된 탈모 억제 또는 발모 촉진용 조성물
KR102221365B1 (ko) * 2019-05-07 2021-03-02 (주)케어젠 트롤록스-펩타이드 결합체 및 그의 용도
CN110755286A (zh) * 2019-11-18 2020-02-07 童婧 一种有助于生发的发际线填充组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2217319A (en) * 1988-04-19 1989-10-25 Synpharm Ltd Racemic and optically active fatty amino acids, their homo- abd hetero-oligomers and conjugates, the process of their production, their pharmaceutical composi
AU729411B2 (en) * 1997-01-23 2001-02-01 Taisho Pharmaceutical Co., Ltd. Sustained release hair growth preparation
TR200302077T4 (tr) 1999-11-29 2004-01-21 F. Hoffmann-La Roche Ag 2-(3,5-Bis-Trifluorometil-fenil)-N-metil-N- (6-morfonil-4-il-4-O-tolil-piridin-3-il)- izobütiramit
FR2826262B1 (fr) 2001-06-26 2005-02-25 Oreal Composition cosmetique ou dermatologique comprenant une association entre un compose de la famille des n-acylaminoamides et au moins un compose agissant sur la chute ou la repousse des cheveux
US20040142853A1 (en) * 2002-11-07 2004-07-22 Procyte Corporation Stimulation of hair growth by compositions containing peptide copper complexes and minoxidil
FR2857597B1 (fr) * 2003-07-18 2008-01-25 Inst Europeen Biolog Cellulair Utilisation de conjugues peptidiques pour la preparation de compositions destinees au traitement preventif et curatif de l'alopecie.
JP4506203B2 (ja) 2004-02-27 2010-07-21 株式会社デンソー 樹脂部材の継手構造、レーザ溶着方法及び電気機器の樹脂筐体
ES2355571T3 (es) * 2004-03-26 2011-03-29 Dsm Ip Assets B.V. Conjugados de ácidos arilalquílicos con aminoácidos y péptidos para usos cosméticos.
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
US20090081145A1 (en) 2005-12-23 2009-03-26 Aplagen Gmbh Process for forming disulphide bridges
EP1998809B1 (en) * 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
US20110293526A1 (en) 2008-11-20 2011-12-01 University Of Southern California Compositions and methods to modulate hair growth
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
KR101198918B1 (ko) 2009-09-01 2012-11-07 (주)케어젠 Ｗｎｔ１０?유래 펩타이드 및 그의 용도
US20110306546A1 (en) * 2010-06-10 2011-12-15 Alvi Armani Genomics Inc. Compositions for increasing hair growth and decreasing hair loss
KR20120011632A (ko) 2010-07-29 2012-02-08 애경산업(주) 미녹시딜을 함유한 모발 세정제 조성물 및 이의 제조 방법
CN103547282A (zh) * 2011-01-21 2014-01-29 Igisu株式会社 秃头症治疗剂
KR101285259B1 (ko) * 2011-08-04 2013-07-11 (주)케어젠 Ｗｎｔ 계열 유래 펩타이드 및 이의 용도
EP3345613B1 (en) 2015-09-01 2023-05-10 Il Dong Pharmaceutical Co., Ltd. Composition for use in treating cancer or an angiogenesis-related disease comprising a fusion protein of a tumor-penetrating peptide and an anti-vegf agent
KR102160566B1 (ko) 2019-01-16 2020-09-28 (주)케어젠 미녹시딜과 펩타이드의 결합체

Also Published As

Publication number Publication date
KR101948238B1 (ko) 2019-02-14
CN109715217B (zh) 2022-07-29
JP2021080273A (ja) 2021-05-27
CA3034066C (en) 2021-02-16
MY193527A (en) 2022-10-18
ES2933848T3 (es) 2023-02-14
WO2018034453A1 (ko) 2018-02-22
EP3501545A1 (en) 2019-06-26
EP3501545A4 (en) 2019-07-17
US11617796B2 (en) 2023-04-04
AU2017313589B2 (en) 2020-01-30
MX2019001921A (es) 2019-07-08
US20190192677A1 (en) 2019-06-27
KR20180020789A (ko) 2018-02-28
EA038745B1 (ru) 2021-10-13
AU2017313589A1 (en) 2019-03-07
CA3034066A1 (en) 2018-02-22
CL2019000429A1 (es) 2019-04-26
ZA201901534B (en) 2022-05-25
BR112019003077A2 (pt) 2019-07-16
JP2019528289A (ja) 2019-10-10
CN109715217A (zh) 2019-05-03
EP3501545B1 (en) 2022-10-26
JP7050052B2 (ja) 2022-04-07
PH12019500345A1 (en) 2019-12-16

Similar Documents

Publication Publication Date Title
EA201791007A3 (ru) Соединения и их применения для модуляции гемоглобина
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
IN2014DN09931A (ru)
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
EA201591198A1 (ru) Антитела к gdf15
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201391019A1 (ru) Соединения и способы для модуляции киназ, а также показания к их применению
MA37506B1 (fr) Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
SA518400042B1 (ar) مترافق من فيناستيريد مع ببتيد
EA201991798A1 (ru) Стабильные при хранении составы
MY173573A (en) Pyridin-4-yl derivatives
EA201692284A1 (ru) Ниацинамид для стимуляции продуцирования антимикробных пептидов
EA201990526A1 (ru) Конъюгат миноксидила и пептида
EA201891608A1 (ru) Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана
WO2015081306A3 (en) Peptide tyrosinase activators
EA201590041A1 (ru) Твердая форма холиновой соли вемурафениба
WO2018068947A3 (de) Proteinhydrolysate
MX2018007871A (es) Composiciones para el cuidado personal.
CY1123360T1 (el) Ενωσεις oi οποιες εχουν αντιοξειδωτικη δραση εναντι των ελευθερων ριζων και αντιφλεγμονωδη δραση, και αντιστοιχες φαρμακευτικες συνθεσεις για τη φροντιδα του δερματος
RU2013119051A (ru) Тетрапептид и средство, обладающее церебропротекторной и антиамнестической активностями
WO2014080015A3 (en) Hair growth compositions and methods
IN2014DN09812A (ru)
WO2014122638A3 (en) Thalidomide and thalidomide analogues for the stimulation of stem cell factor